Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer

Journal of the National Cancer Institute

Volumn 106, Issue 1, 2014, Pages

  Moutinho, Catia ^a   Martinez Cardús, Anna ^a   Santos, Cristina ^b   Navarro Pérez, Valentin ^b   Martínez Balibrea, Eva ^a   Musulen, Eva ^c   Carmona, F Javier ^a   Sartore Bianchi, Andrea ^d   Cassingena, Andrea ^d   Siena, Salvatore ^d   Elez, Elena ^e   Tabernero, Josep ^e   Salazar, Ramon ^b   Abad, Albert ^b   Esteller, Manel ^a,f,g  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; BRCA1 PROTEIN; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; MESSENGER RNA; OXALIPLATIN; SHORT HAIRPIN RNA; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN, HUMAN; DEOXYCYTIDINE; DRUG DERIVATIVE; PLATINUM COMPLEX; PRKCDBP PROTEIN, HUMAN; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; DNA MICROARRAY; DRUG RESISTANCE; EPIGENETICS; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE IDENTIFICATION; GENE INACTIVATION; GENE LOCUS; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; MTT ASSAY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; SHEEP ERYTHROCYTE; TUMOR SUPPRESSOR GENE; ADJUVANT CHEMOTHERAPY; ADULT; AGED; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CPG ISLANDS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84892650763     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt322     Document Type: Article

References (33)

1. Jemal A. Global burden of cancer: opportunities for prevention. Lancet. 2012;380(9856):1797-1799.
2. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479-2516.
3. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9-23.
4. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002;1(3):227-235.
5. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer. 2003;39(1):112-119.
6. Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 2003;22(5):1169-1173.
7. Pang SK, Yu CW, Guan H, Au-Yeung SC, Ho YP. Impact of oxaliplatin and a novel DACH-platinum complex in the gene expression of HCT116 colon cancer cells. Oncol Rep. 2008;20(5):1269-1276.
8. Atipairin A, Canyuk B, Ratanaphan A. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs. Breast Cancer Res Treat. 2011;126(1):203-209.
9. Stefansson OA, Villanueva A, Vidal A, Marti L, Esteller M. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics. 2012;7(11):1225-1229.
10. Xu Y, Diao L, Chen Y, et al. Promoter methylation of BRCA1 in triplenegative breast cancer predicts sensitivity to adjuvant chemotherapy. Ann Oncol. 2013;24(6):1498-1505.
11. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148-1159.
12. Park YJ, Claus R, Weichenhan D, Plass C. Genome-wide epigenetic modifications in cancer. Prog Drug Res. 2011;67:25-49.
13. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer. 2011;11(10):726-734.
14. Martinez-Cardus A, Martinez-Balibrea E, Bandres E, et al. Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer. Mol Cancer Ther. 2009;8(1):194-202.
15. Bibikova M, Le J, Barnes B, et al. Genome-wide DNA methylation profiling using Infinium(R) assay. Epigenomics. 2009;1(1):177-200.
16. Davalos V, Moutinho C, Villanueva A, et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene. 2012;31(16):2062-2074.
17. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004;54(6):295-308.
18. Xu XL, Wu LC, Du F, et al. Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. Cancer Res. 2001;61(21):7943-7949.
19. Zochbauer-Muller S, Fong KM, Geradts J, et al. Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. Oncogene. 2005;24(41):6249-6255.
20. Lee JH, Kang MJ, Han HY, et al. Epigenetic alteration of PRKCDBP in colorectal cancers and its implication in tumor cell resistance to TNFalphainduced apoptosis. Clin Cancer Res. 2011;17(24):7551-7562.
21. Turner NC, Tutt AN. Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? Breast Cancer Res. 2012;14(6):115.
22. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet. 2012;13(10):679-692.
23. Peeters M, Douillard JY, Van Cutsem E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol. 2013;31(6):759-765.
24. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6(5):279-286.
25. Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET Receptor drives resistance to anti-EGFR Therapies in colorectal cancer.Cancer Discov. 2013;3(6):658-673.
26. Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. NeuroOncol. 2012;14(Suppl 4):iv100-108.
27. Wang YQ, Yan Q, Zhang JR, et al. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression. J Obstet Gynaecol Res. 2013;39(2):549-554.
28. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92(7):564-569.
29. Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001;10(26):3001-3007
30. Fernandez AF, Assenov Y, Martin-Subero JI, et al. A DNA methylation fingerprint of 1628 human samples. Genome Res. 2012;22(2):407-419.
31. McMahon KA, Zajicek H, Li WP, et al. SRBC/cavin-3 is a caveolin adapter protein that regulates caveolae function. EMBO J. 2009;28(8):1001-1015.
32. Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8)472-484.
33. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011;1(7):598-607.